NASDAQ:JNCE • US4811161011
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for JOUNCE THERAPEUTICS INC (JNCE).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-02-24 | SMBC Nikko | Downgrade | Outperform -> Neutral |
| 2023-02-23 | Raymond James | Downgrade | Outperform -> Market Perform |
| 2023-01-03 | Piper Sandler | Maintains | Overweight |
| 2022-11-11 | Raymond James | Downgrade | Strong Buy -> Outperform |
| 2022-08-31 | Raymond James | Maintains | Strong Buy |
| 2022-08-05 | HC Wainwright & Co. | Maintains | Buy |
| 2022-05-23 | Piper Sandler | Maintains | Overweight |
| 2022-05-11 | Baird | Downgrade | Outperform -> Neutral |
| 2022-05-06 | Raymond James | Upgrade | Outperform -> Strong Buy |
| 2022-02-04 | Cowen & Co. | Upgrade | Market Perform -> Outperform |
| 2021-11-05 | Raymond James | Maintains | Outperform |
| 2021-09-14 | Raymond James | Upgrade | Market Perform -> Outperform |
| 2021-03-15 | Piper Sandler | Initiate | Overweight |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 62.3M -57.88% | 26.907M -56.81% | 82M 204.75% | -100.00% | 70.701M | 119.97M 69.69% | 199.8M 66.54% | 407.53M 103.97% | 492.14M 20.76% | 549.75M 11.71% | ||
| EBITDA YoY % growth | -41.7M -173.54% | -88.229M -111.58% | -50.155M 43.15% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -45.1M -185.42% | -91.056M -101.90% | -52.242M 42.63% | -152.16M -191.26% | -148.175M 2.62% | -90.484M 38.93% | -71.502M 20.98% | -25M 65.04% | 138.22M 652.88% | 198.57M 43.66% | 242.07M 21.91% | |
| Operating Margin | -72.39% | -338.41% | -63.71% | N/A | N/A | -127.98% | -59.60% | -12.51% | 33.92% | 40.35% | 44.03% | |
| EPS YoY % growth | -1.47 -190.18% | -1.84 -25.17% | -0.99 46.20% | -1.36 -37.55% | -1.05 22.85% | -1.26 -19.90% | -1.16 8.10% | -0.60 48.46% | 2.60 535.90% | 3.00 15.29% | 3.16 5.44% |
All data in USD
| Q1 / 23 | Q2 / 23 | Q3 / 23 | Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.71 0.83% | -0.23 63.91% | -0.21 65.15% | -0.21 -121.34% | -0.27 62.86% | -0.27 -13.04% | -0.26 -21.95% | -0.26 -21.95% |
| Revenue Q2Q % growth | -100.00% | |||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -37.332M 0.35% | -12.75M 62.18% | -11.016M 64.92% | -11.07M -121.99% | -14.28M 61.75% | -14.28M -12.00% | -13.77M -25.00% | -13.77M -24.40% |
All data in USD
13 analysts have analysed JNCE and the average price target is 1.65 USD. This implies a price decrease of -12.29% is expected in the next year compared to the current price of 1.88.
JOUNCE THERAPEUTICS INC (JNCE) will report earnings on 2023-08-02.
The consensus EPS estimate for the next earnings of JOUNCE THERAPEUTICS INC (JNCE) is -0.71 USD and the consensus revenue estimate is 0 USD.
The consensus rating for JOUNCE THERAPEUTICS INC (JNCE) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.